Pages that link to "Q34318656"
Jump to navigation
Jump to search
The following pages link to Antitumor activity of a kinesin inhibitor (Q34318656):
Displaying 50 items.
- KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells (Q21245466) (← links)
- Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference (Q24300469) (← links)
- Cell cycle-dependent dynamics and regulation of mitotic kinesins in Drosophila S2 cells (Q24534293) (← links)
- Monastrol inhibition of the mitotic kinesin Eg5. (Q24540254) (← links)
- Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer (Q24615262) (← links)
- NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site (Q24623319) (← links)
- Pathway of ATP hydrolysis by monomeric kinesin Eg5 (Q24644762) (← links)
- Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line (Q25256692) (← links)
- The structure of the ternary Eg5–ADP–ispinesib complex (Q27673428) (← links)
- Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity (Q27676766) (← links)
- KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers (Q28251179) (← links)
- Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase (Q28296466) (← links)
- Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol (Q30477178) (← links)
- Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. (Q30494019) (← links)
- Nuclear envelope-associated dynein drives prophase centrosome separation and enables Eg5-independent bipolar spindle formation (Q30528108) (← links)
- Single-molecule inhibition of human kinesin by adociasulfate-13 and -14 from the sponge Cladocroce aculeata (Q30557802) (← links)
- Salt-inducible kinase 3 is a novel mitotic regulator and a target for enhancing antimitotic therapeutic-mediated cell death (Q30577179) (← links)
- Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein (Q33229942) (← links)
- Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. (Q33566736) (← links)
- Mechanism and regulation of kinesin-5, an essential motor for the mitotic spindle. (Q33666502) (← links)
- A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor (Q33812795) (← links)
- Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. (Q33926815) (← links)
- A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias (Q34238046) (← links)
- Kinesins and cancer. (Q34289839) (← links)
- Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia (Q34385571) (← links)
- Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells (Q34515624) (← links)
- A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study (Q34647484) (← links)
- Anaphase catastrophe is a target for cancer therapy (Q34700600) (← links)
- Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. (Q34856951) (← links)
- Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors (Q35087706) (← links)
- Chemotherapeutic approaches for targeting cell death pathways (Q35094229) (← links)
- Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma (Q35163926) (← links)
- Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction (Q35190903) (← links)
- Kinesin molecular motor Eg5 functions during polypeptide synthesis. (Q35210993) (← links)
- Killing cells by targeting mitosis (Q35754713) (← links)
- Dimeric Eg5 maintains processivity through alternating-site catalysis with rate-limiting ATP hydrolysis (Q35785839) (← links)
- Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells (Q35844479) (← links)
- Aurora-kinase inhibitors as anticancer agents (Q35968406) (← links)
- A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors (Q36087894) (← links)
- Overexpression of Kinesin Family Member 20A Correlates with Disease Progression and Poor Prognosis in Human Nasopharyngeal Cancer: A Retrospective Analysis of 105 Patients (Q36247439) (← links)
- The structure of microtubule motor proteins (Q36288562) (← links)
- Identification of prognostic genes in kidney renal clear cell carcinoma by RNA‑seq data analysis (Q36297470) (← links)
- Getting in sync with dimeric Eg5. Initiation and regulation of the processive run. (Q36492499) (← links)
- A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours (Q36494207) (← links)
- Inhibitors of mitotic kinesins: next-generation antimitotics (Q36558125) (← links)
- Histone H3 Phosphorylation in Human Skin Histoculture as a Tool to Evaluate Patient's Response to Antiproliferative Drugs (Q36598525) (← links)
- Development of new cancer therapeutic agents targeting mitosis (Q36623076) (← links)
- Targeted anti-mitotic therapies: can we improve on tubulin agents? (Q36717905) (← links)
- Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice (Q37111373) (← links)
- Ubiquitin ligase RNF20/40 facilitates spindle assembly and promotes breast carcinogenesis through stabilizing motor protein Eg5. (Q37223043) (← links)